Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of aH5N6c Booster Vaccine in Adults Primed With aH5N1c or Unprimed
NCT05422326Phase 2Completed
- Sponsor
- CSL Seqirus
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of MF59-adjuvanted H5N6 cell culture-derived influenza vaccine in influenza (3 arms), sponsored by CSL Seqirus. Primary endpoints: Geometric Mean Titer of Hemagglutination Inhibition Antibodies Against the H5N6 Strain at Day 43, Geometric Mean Fold Increase of Hemagglutination Inhibition Antibodies Against the H5N6 Strain at Day 43 and 2 more. Started Jul 2022; status: completed.
02
Drugs
MF59-adjuvanted H5N6 cell culture-derived influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05422326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422326.